Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xolatryp
- Development stage
- Phase 2
- Lead developer
- Nyrada
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Xolatryp** (formerly NYR-BI03) is a first-in-class small-molecule inhibitor of Transient Receptor Potential Canonical (TRPC) ion channels developed by Nyrada Inc. for neuroprotection and cardioprotection. It limits pathological calcium ion entry into cells, stabilizes mitochondrial function, reduces reactive oxygen species damage, and mitigates secondary injury in conditions like ischemic stroke, traumatic brain injury (TBI), and myocardial ischemia-reperfusion injury (MIRI). Preclinical studies have demonstrated significant efficacy, including 42% rescue of brain tissue in stroke models and preservation of mitochondrial health in penetrating TBI models.[4][6][8][12]
- Brand names
- Xolatryp
02
Targets
TRPC3TRPC6 (Transient receptor potential canonical type 6)TRPC7TRPC (TRPC family)
Beyond the preview
Go deeper on Xolatryp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xolatryp.